Project Grant HT94252411066
Award Date
9/15/24
Completion Date
9/14/28
Dollars Obligated
$2.4M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
The University of Texas MD Anderson Cancer Center received a $1,619,997 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on targeting ferroptosis and mitochondrial pathways in acute myeloid leukemia. The 3-year award, which commenced on September 1, 2023, will support preclinical studies, clinical trials, and other research activities at the cancer center's facilities in Houston, Texas. As a component...
The federal Project Grant award of $1,882,607.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award will support research conducted by The University of Texas M.D. Anderson Cancer Center to leverage prostate cancer's unique lipid metabolism to induce therapeutic ferroptosis. The research aims to transform healthcare for military service members and the broader public by investigating innovative approaches...
The federal Project Grant award, with ID HT94252510182, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The $1,306,991.00 award, with a performance period from Aug 1, 2025 to Jul 31, 2029, is funding research at the University of Texas MD Anderson Cancer Center to develop organoid-based models and therapeutic approaches for TP53-mutated acute myeloid leukemia. This research aims to transform healthcare for...
The University of Texas MD Anderson Cancer Center received a $567,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on September 1, 2024, will fund research targeting myeloid mimicry in renal medullary carcinoma, with a completion date of August 31, 2027. Through this federal grant, MD Anderson Cancer Center will conduct innovative scientific studies, ranging from basic laboratory research to advanced...
This $3,945,543 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports cancer research and care initiatives at the University of Texas MD Anderson Cancer Center (MD Anderson). The award will fund a 4-year clinical research extension project to advance progress, precision, and equity in breast cancer care. MD Anderson, a leading comprehensive cancer center, will utilize the funding to conduct research activities that...
The federal Project Grant award, with ID HT94252410992, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, totaling $2,710,479.00, will fund a research initiative led by the University of Texas M.D. Anderson Cancer Center to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. The award's performance period is from August 15, 2024 to...
The federal Project Grant award, funded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, provides $1,635,000.00 to The University of Texas M.D. Anderson Cancer Center to conduct research aimed at targeting the PCTK1 driver kinase in combination with ferroptosis inducers to combat breast cancer brain metastasis. The project will be performed over a 3-year period from June 1, 2025 to May 31, 2028. As a prominent academic cancer research and...
This $1,619,723 federal Project Grant award from the Department of Defense's Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides funding to The University of Texas MD Anderson Cancer Center to conduct research targeting novel mediators of breast cancer brain metastasis. The award period runs from April 1, 2024 to March 31, 2027, with the goal of developing new treatments, improving patient care, and advancing scientific understanding in this...
This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $1,444,922.00 to the University of Texas MD Anderson Cancer Center (MD Anderson) to conduct research on a novel epigenetic determinant in metastatic prostate cancer. The award period is from September 15, 2024 to September 14, 2027. MD Anderson, a comprehensive cancer research and treatment center, will utilize this funding to carry out basic,...
The University of Texas MD Anderson Cancer Center, a component of the University of Texas System, received a $486,000 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The 3-year grant, with a start date of September 30, 2023, supports research targeting the PRMT5 protein in melanoma with MTAP gene loss. The funding will enable preclinical studies, including evaluating novel treatments, to advance the understanding and...